Zusammenfassung
Ziele der Diabetestherapie sind Symptomfreiheit, Vermeidung von Spätkomplikationen und Verminderung der Letalität. Dieses wird in der Regel durch eine möglichst optimale Blutzuckereinstellung erreicht. Die kürzlich veröffentlichten Ergebnisse der UKPDS-Studie haben gezeigt, daß eine intensivierte Diabetestherapie mit einem HbA1c-Wert unter 7% über die ersten 10 Jahre nach der Diagnose die mikrovaskulären Komplikationen senkt (UK Prospective Diabetes Study Group 1998a).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bailey C.J., Path M.R.C., Turner R.C. (1996): Metformin. New Engl. J. Med. 334: 574–579.
Berger M., Köbberling J., Windeier J. (1996): Wirksamkeit und Wertigkeit der Acarbose. Dtsch. Ärztebl. 93: B-443–444.
Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W. et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 121: 928–935.
De Fronzo R.A., Goodman M. (1995): Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. New Engl. J. Med. 333: 541–549.
Dills D.G., Schneider J. (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm. Metab. Res. 28: 426–429.
Draeger K.E., Wernicke-Panten K., Lomp H.-J., Schüler E., Roßkamp R. (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibendamide. Horm. Metab. Res. 28: 419–425.
Dunn C.J., Peters D.H. (1995): Metformin-A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721–749.
Everett J., Kerr D. (1994): Changing from porcine to human insulin. Drugs 47: 286–296.
Holman R.R., Mayon White V., Orde-Peckar C., Steemson J., Smith B. et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.
Karam J.H., Etzwiler D.D. (eds.) (1983): International symposium on human insulin. Diabetes Care 6: 1–68.
Koivisto V.A. (1998): The human insulin analogue insulin lispro. Ann. Med. 30: 260–266.
Langtry H.D., Balfour J.A. (1998): Glimepiride. A review of its use in the management of Type 2 diabetes mellitus. Drugs 55: 563–584.
Nathan D.M. (1998): Some answers, more controversy, from UKPDS. (Commentary). Lancet 352: 832–833.
Rosenstock J., Samols E., Muchmore D.B., Schneider J. (1996): Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19: 1194–1199.
Sachse G. (1994): Acarbose-Behandlung als neues Therapieprinzip. Dtsch. Ärztebl. 91, Suppl. 15–17.
Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. (1995): Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl. J. Med. 333: 550–554.
UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.
UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.
Veneman T.P., Tack C.J., van Haeften T.W. (1998): The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe. Neth. J. Med. 52: 179–186.
Wilde M.I., McTavish D. (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mengel, K. (2000). Antidiabetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57215-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-57215-9_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66376-8
Online ISBN: 978-3-642-57215-9
eBook Packages: Springer Book Archive